2012³â 2¿ù 27ÀÏ-3¿ù 2ÀÏ · Hilton San Diego Bayfront Hotel · San Diego, CA
Read a sample of who attended the conference in 2011.
Updated: March 16, 2011
"Good topics, good people, discussions on the point!"
- J. Friedle, Managing Director, Atoll GmbH
"I greatly enjoyed the quality of the case studies that were presented. The speakers were very open to sharing ideas and lessons learned from real-world projects."
- M. Pujols, Manufacturing Director, MedImmune, LLC
"These well-organized conferences cover the key topics and areas of interest across the biotech industry. They provide an excellent forum to exchange ideas and create networking contacts."
- W.D. Taylor, Director, Business Development, Pfenex
"A fluid representation of the changing landscape of our industry, allowing for invaluable networking opportunities and topical discussions."
- B.D. Monroe, Process Science Fellow, Life Technologies
Biopharmaceutical Development & Production Week 2012
(»ý¹°ÀǾàǰ °³¹ß ¹× Á¦Á¶ 2012)
2012³â 2¿ù 27ÀÏ-3¿ù 2ÀÏ | ¹Ì±¹, »÷µð¿¡°í
IBC°¡ ÁÖÃÖÇÏ´Â Biopharmaceutical Development & Production Week´Â 9°³ ÄÁÆÛ·±½º°¡ ¸¶·ÃµÇ¾ú°í, Âü°¡ÀÚ°¡ ¿øÇÏ´Â ³»¿ëÀ» ¼±ÅÃÇÒ ¼ö ÀÖ¾î ÃÖÀûÀÇ Á¤º¸¸¦ ¾òÀ» ¼ö ÀÖ´Â Çà»ç·Î ±¸¼ºµÇ¾ú½À´Ï´Ù.
2012³â 2¿ù 27ÀϺÎÅÍ 3¿ù 2ÀϱîÁö »÷µð¿¡°í¿¡¼ °³ÃֵǴ À̹ø Çà»ç¿¡ ¸¹Àº °ü½É ºÎŹ µå¸³´Ï´Ù.
1ÁÖÀϰ£ ÁøÇàµÇ´Â º» Çà»ç´Â 9°³ ÄÁÆÛ·±½º·Î ±¸¼ºµÇ¾î ÀÖ½À´Ï´Ù.
![]() |
Antibody Development & Production(Ç×ü °³¹ß°ú Á¦Á¶) ¹ÙÀÌ¿ÀÇÁ·Î¼¼½ÌÀÇ ¹®Á¦Á¡ ±Øº¹À» À§ÇÑ ±â¾÷ Çù·Â°ú ±â¼ú ¹× °úÇÐ Çõ½ÅÀÇ ÅëÇÕ 2012³â 2¿ù 29ÀÏ¡3¿ù 2ÀÏ » ÄÁÆÛ·±½º °³¿ä » °úÇÐÀÚ¹®À§¿øÈ¸ » ¾ÆÁ¨´Ù |
![]() |
Process and Product Validation (ÇÁ·Î¼¼½º¿Í Á¦Ç°ÀÇ °ËÁõ) Áö¼ÓÀû °ËÁõÀ» À§ÇÑ ¼ö¸íÁÖ±â¿Í ¸®½ºÅ© ±â¹Ý Á¢±Ù¹ýÀ¸·ÎÀÇ À̵¿ 2012³â 2¿ù 27ÀÏ¡28ÀÏ » ÄÁÆÛ·±½º °³¿ä » ¾ÆÁ¨´Ù |
![]() |
Technology Transfer for Biopharmaceuticals (»ý¹°ÀǾàǰÀÇ ±â¼ú ÀÌÀü) ½Ã¼³ÀÇ Ã³¸® ´É·Â Çâ»ó°ú Á¦Á¶ ½Ã°£ ´ÜÃàÀ» ÅëÇØ ±â¼ú ÀÌÀü¿¡ ÀÇÇÑ Á¦ÈÞ ¼º°ú º¸Àå February 27-28, 2012 » ÄÁÆÛ·±½º °³¿ä » ¾ÆÁ¨´Ù |
![]() |
Outsourcing Manufacturing of Biopharmaceuticals (»ý¹°ÀǾàǰ Á¦Á¶¾÷¹« ¾Æ¿ô¼Ò½Ì) ÀǾàǰ Á¦Á¶À§Å¹±â°ü(CMO)°úÀÇ Á¦ÈÞ¿Í °øµ¿ °³¹ßÀÇ ¼º°øÀ» ÅëÇÑ ¸®½ºÅ© Àý°¨ ¹× »ý»ê¼º Çâ»ó ½ÇÇö 2012³â 2¿ù 27ÀÏ¡28ÀÏ » ÄÁÆÛ·±½º °³¿ä » ¾ÆÁ¨´Ù |
![]() |
Recombinant Protein & Complex Biologic Development & Production (À¯ÀüÀÚ ÀçÁ¶ÇÕ ´Ü¹éÁú ¹× º¹ÀâÇÑ »ý¹°Á¦Á¦ °³¹ß°ú »ý»ê) »õ·Î¿î ºÐÀÚ °³¹ß¿¡ °ü·ÃµÈ ±â¼ú ¹× °úÇÐ ºÐ¾ß ¹®Á¦Á¡ ±Øº¹À» À§ÇÑ Á¢±Ù¹ý 2012³â 2¿ù 29ÀÏ¡3¿ù 2ÀÏ » ÄÁÆÛ·±½º °³¿ä » °úÇÐÀÚ¹®À§¿øÈ¸ » ¾ÆÁ¨´Ù |
![]() |
Analytical Technologies for Biotherapeutic Development (»ý¹°ÀǾàǰ °³¹ßÀ» À§ÇÑ ºÐ¼® ±â¼ú) °³¹ß ÃʱâºÎÅÍ ÃÖÁ¾ ´Ü°è±îÁöÀÇ »õ·Î¿î ºÐ¼® Á¢±Ù¹ý°ú ±â¼ú µµÀÔ¿¡ ÀÇÇÑ ÇÁ·ÎÁ§Æ® ÃßÁø 2012³â 2¿ù 29ÀÏ¡3¿ù 2ÀÏ » ÄÁÆÛ·±½º °³¿ä » °úÇÐÀÚ¹®À§¿øÈ¸ » ¾ÆÁ¨´Ù |
![]() |
Biopharmaceutical Raw Materials throughout the Product Lifecycle (Á¦Ç° ¼ö¸íÁֱ⿡ °ü·ÃµÈ °¢Á¾ »ý¹°ÀǾàǰ ¿ø·á) Upstream°ú Downstream °³¹ß °øÁ¤ ¹× ÀÓ»ó½ÃÇè°ú »ó¾÷ »ý»ê ´Ü°è¿¡¼ ¿ø·áÀÇ º¯µ¿¼ºÀÇ È®ÀÎ, °Ë»ç, °ü¸®¿¡ ÀÇÇÑ ¸®½ºÅ© Àý°¨ Àü·« 2012³â 2¿ù 27ÀÏ¡28ÀÏ » ÄÁÆÛ·±½º °³¿ä » ¾ÆÁ¨´Ù |
![]() |
Viral Safety for Biologicals (»ý¹°Á¦Á¦ÀÇ ¹ÙÀÌ·¯½º ¾ÈÀü¼º) Upstream, Downstream, Á¦Á¶ °øÁ¤¿¡¼ ¹ÙÀÌ·¯½º °ËÃâ, ¿¹¹æ, Ä¡·á¸¦ À§ÇÑ Àü·«, ±â¼ú ¹× ±ÔÁ¦ Àü¸Á 2012³â 2¿ù 27ÀÏ¡28ÀÏ » ÄÁÆÛ·±½º °³¿ä » ¾ÆÁ¨´Ù |
![]() |
Biobetters & Biosimilars: Technologies and Development Strategies (¹ÙÀÌ¿Àº£ÅÍ¿Í ¹ÙÀÌ¿À½Ã¹Ð·¯£º±â¼ú Àü·«°ú °³¹ß Àü·«) ¹Ì·¡ »ç¾÷¼º°ú ½ÇÁúÀûÀÎ ºñÁö´Ï½º ±âȸ ºÐ¼® ´Ü°è 2012³â 2¿ù 29ÀÏ¡3¿ù 2ÀÏ » ÄÁÆÛ·±½º °³¿ä » °úÇÐÀÚ¹®À§¿øÈ¸ » ¾ÆÁ¨´Ù |




